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Phase-Based Manganese Enhanced MRI, a New
Methodology to Enhance Brain Cytoarchitectural
Contrast and Study Manganese Uptake
Rajika Maddage,1 Jose P. Marques,2* and Rolf Gruetter1,2,3
Purpose: As the magnetic susceptibility induced frequency
shift increases linearly with magnetic field strength, the present
work evaluates manganese as a phase imaging contrast agent
and investigates the dose dependence of brain enhancement
in comparison to T1-weighted imaging after intravenous
administration of MnCl2.
Methods: Experiments were carried out on 12 Sprague-
Dawley rats. MnCl2 was infused intravenously with the follow-
ing doses: 25, 75, 125 mg/kg (n¼4). Phase, T1-weighted
images and T1 maps were acquired before and 24h post
MnCl2 administration at 14.1 Tesla.
Results: Manganese enhancement was manifested in phase
imaging by an increase in frequency shift differences
between regions rich in calcium gated channels and other
tissues, together with local increase in signal to noise ratio
(from the T1 reduction). Such contrast improvement allowed
a better visualization of brain cytoarchitecture. The measured
T1 decrease observed across different manganese doses
and in different brain regions were consistent with the
increase in the contrast to noise ratio (CNR) measured by
both T1-weighted and phase imaging, with the strongest var-
iations being observed in the dentate gyrus and olfactory
bulb.
Conclusion: Overall from its high sensitivity to manganese
combined with excellent CNR, phase imaging is a promising
alternative imaging protocol to assess manganese enhanced
MRI at ultra high field. Magn Reson Med 72:1246–1256,
2014. VC 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Contrast agents have been regularly used to improve the
contrast between and within soft tissues and overcome
the limits of the available contrast originating from dif-
ferences in relaxation times (T1/T2), spin mobility (diffu-
sion, perfusion), and spin density. By affecting the
longitudinal and the transverse relaxation rate of sur-
rounding water protons, paramagnetic and super-
paramagnetic contrast agents enhance the contrast to
noise ratio (CNR) by either increasing or reducing the
signal in targeted regions.
Manganese (Mn2þ) has proven to be a very interesting
MR contrast agent. Being an analog to Ca2þ and para-
magnetic (due to the five unpaired electrons on the 3d
electronic orbital), Mn2þ can enter voltage gated calcium
channels and enhance the signal in T1-weighted images
in regions of Mn2þ accumulation due to local T1 shorten-
ing. Studies using Mn2þ as a contrast agent have been
limited to animal models because of its high cellular tox-
icity, causing heart and hepatic failure (1,2), and, in the
case of chronic Mn2þ exposure, leading to a form of Par-
kinsonism (3). In rodents, various in vivo brain studies
have been performed to map neuronal connections (4),
functional activity (5), and enhance the brain cytoarchi-
tecture (6,7), demonstrating to be an useful MRI marker
of neuronal activity and calcium influx in tissues. As
Mn2þ is not able to cross the blood brain barrier (BBB)
three main approaches have been used to deliver Mn2þ
to the targeted brain regions: infusion of Mn2þ followed
by BBB disruption (8); local injection (4); systemic
administration, with the enhancement being first
observed in choroid plexus, cerebrospinal fluid, and
only latter in tissues (9). The least invasive method, sys-
temic administration, has enabled to depict several struc-
tures rich or with active voltage gated calcium channels
such as layers in the hippocampus, cortex, and olfactory
bulb (6,7,10).
Over the recent years, phase imaging has gained a sig-
nificant interest (11,12) thanks to the increase of the
magnetic fields available on clinical MR scanners. At
fields above 3 Tesla, it was shown that the contrast to
noise ratio (CNR) observed in phase images between gray
and white matter was superior to that of conventional
magnitude images, yielding additional anatomical infor-
mation in the brain including the observation of subcort-
ical contrast (11,12). In rodent studies, phase imaging at
high magnetic field with an in-plane resolution of 33 mm
was found to give anatomical details with clear depiction
of cytoarchictectural features such as hippocampal
fields, cortical and cerebellar layers, structures typically
not easily discernible in T1, T2, or T2* magnitude images
(13).
The observed contrast in phase imaging is due to
magnetic susceptibility induced frequency shifts which
increase linearly with the magnetic field strength. Even
though its origin is still not clear, many mechanisms
have been proposed (11,14,15) with tissue bulk mag-
netic susceptibility playing a major role in modulating
the phase shifts observed across the brain. The origin of
such bulk susceptibility has been found to have
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different origins in different brain regions. In humans,
the contrast observed in deep gray matter nuclei and in
intracortical contrast has been attributed to local iron
concentration (16,17), while in rodents, the susceptibil-
ity difference responsible for gray and white matter
contrast has been demonstrated to have myelin origin
(18–20).
To the best of our knowledge, manganese enhanced
MRI (MEMRI) has only been assessed using T1 contrast.
The increasingly strong magnetic fields available poten-
tiate stronger Mn2þ magnetic susceptibility effects, mak-
ing phase imaging a natural candidate to profit from
Mn2þ uptake in tissues. Mn2þ should induce a phase
shift observable with phase imaging and, combined
with its high sensitivity to endogenous magnetic sus-
ceptibility distribution and high CNR, could be
exploited to further enhance neural architecture in ani-
mal models.
The present work was designed to investigate the
above hypothesis by assessing Mn2þ potential input on
phase imaging at 14.1T and to determine the level of
phase contrast enhancement obtained following sys-
temic administration in comparison to the standard
imaging protocol used in MEMRI, namely T1-weighted
imaging. The phase shift and the contrast enhancement
as a function of the Mn2þ dose were also investigated
to assess its linearity and sensitivity in comparison to
T1-weighted imaging. Finally, the potential of quantifi-
cation of Mn2þ uptake based on phase imaging is
addressed.
METHODS
Animal Preparation
Experiments were carried out in 12 male Sprague-
Dawley rats (weighting 200–300 g). All animal experi-
ments were conducted according to federal and local eth-
ical guidelines and the protocols were approved by the
local regulatory body.
The Mn2þ administration protocol consisted of a tail
vein infusion at a rate of 1.0 mL/h of an isotonic MnCl2
(Sigma-Aldrich, St Louis, MO) solution prepared with a
concentration of 120 mM. During MnCl2 infusion, all
rats were anesthetized under 2% isoflurane and their
body temperature was maintained at 38 6 0.5C by
means of a heating pad. Four different doses of MnCl2
were used: 25 (4 animals), 75 (4 animals), 125 (4 ani-
mals), and 175 mg/kg. The dose of 175 mg/kg was dis-
carded due to a high mortality rate observed (90%). After
infusion, rats were returned to their cages with free
access to food and water and held under a 12 h/12 h
light/dark regimen.
MRI was performed prior and 24h post MnCl2 infu-
sion. During the MR image acquisition, the rats were
kept under anesthesia (1.5–2% isoflurane delivered
through a face mask) and were fixed using a custom
made stereotaxic holder. Respiration rate was monitored
using a pressure pillow placed under the rat’s abdomen
(respiration rate of 60 6 3 breaths per minute).
Body temperature was monitored using a rectal tempera-
ture probe and maintained at 38 6 0.5C by a heated
water bath.
Phantom Study: MnCl2 Relaxometry at 14.1T
A phantom containing seven cylindrical tubes with dif-
ferent Mn2þ concentration (from 0 mM to 200 mM dis-
solved in distilled water) was produced. From the T1 (1/
R1) and frequency shift maps measured across the Mn
2þ
concentrations, it was possible to compute the relaxivity
parameters r1 and magnetic susceptibility x([Mn
2þ]).
(Details of the imaging and processing protocols will be
given in the MRI and Phantom Data sections
respectively).
MRI
All scans were performed on a 14.1T/26 cm horizontal
bore magnet (Varian/Magnex Scientific). The MnCl2
relaxometry protocol (performed on the phantom
described on the previous paragraph) was acquired using
a high pass birdcage coil with an inner diameter of 46
mm and length of 30 mm. In vivo rat brain images were
acquired using a home built quadrature surface coil as
radiofrequency (RF) transceiver with two geometrically
decoupled 21 mm loops resonating at 600 MHz. To take
full advantage of the high signal to noise ratio (SNR), the
surface coil was carefully and systematically positioned
over the brain regions under investigation, regions
known to be rich/or with active voltage gated calcium
channels that are susceptible to Mn2þ uptake (6,7): olfac-
tory bulb (OB) including the olfactory nerve layer (ONL),
glomerular layer (GL) and mitral cell layer (ML); the hip-
pocampus (HC) including the CA formation of the hippo-
campus and the dentate gyrus. To take advantage of
using thick slices (compared with the in-plane resolu-
tion) and to further improve the SNR without signifi-
cantly increasing partial volume effects, both the slices
covering the hippocampus and the olfactory bulb were
positioned coronally.
Magnetic field homogeneity was adjusted using FAST-
MAP (21) in a large volume located in the different
regions. Water spectra linewidth of 21–26 Hz were
obtained over a typical voxel size of 7  10  6 mm3 in
cortex/hippocampus regions and 2  2  4 mm3 in the
OB. The complete acquisition protocol described in the
following paragraph was applied before and 24h post
Mn2þ systemic administration.
T1 Mapping
T1 mapping was performed using a multi-slice multi-
shot inversion-recovery Look-Locker Segmented Echo
Planar Imaging sequence (22,23). A slice-selective 180
adiabatic pulse (hyperbolic secant, hs8) was used to
invert the magnetization followed by low flip angle
slice-selective pulses (FA ¼ 20) that sampled the inver-
sion recovery curve in 20 points with inversion times
from 50 ms to 4050 ms (with an inter-excitation delay of
200 ms). The repetition time (TR) was set to 24.5 s, suffi-
cient for the full recovery of the longitudinal magnetiza-
tion allowing 6 slices to be acquired per TR while the
interexcitation delay was chosen to guarantee the accu-
racy of T1 values down to 400 ms (22,23). The echo time
(TE) of the EPI readout was kept short (TE ¼ 5.7 ms) to
avoid through slice signal dephasing. K-space was
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acquired in a segmented manner (16 shots) to reduce
geometrical distortions due to magnetic susceptibility
differences (tissue/air). Other imaging parameters: field
of view (FOV) ¼ 22*22 mm2, resolution ¼ 172*172*800
mm3, number of slices ¼ 6 and total acquisition time ¼
14 min. For Nyquist ghost correction, a readout polarity
reversal scheme was used (24).
T1-Weighted and Phase Images
T1-weighted and phase images were acquired using a
gradient echo multi-slice sequence (GEMS) with respira-
tion gating to reduce respiration induced artifacts which
suggested that all images were acquired with a TR1s.
The small and slow variations in respiration rate could
only generate a maximum signal variation (due to TR
fluctuations) of 64%, which was considered too small to
require any extra corrections.
For phase images, the flip angle was optimized to max-
imize the signal intensity in the specific regions of inter-
est. The echo time (16 ms) was chosen to approximately
match the gray matter T2* and, hence, optimize phase
contrast (13). The acquisition bandwidth was chosen to
maximize signal without introducing effective resolution
reduction due to T2* decay during the readout (tacq ¼
15.9 ms).
For T1-weighted images, echo time was reduced (5 ms)
and acquisition bandwidth was increased to emphasize
the T1 contrast while maintaining sufficient SNR. The
flip angle was chosen to be close to 90 to enhance the
T1 contrast in the regions where contrast enhancement
was expected, while avoiding undesirable inversions in
the regions closest to the coil.
Summary of acquisition parameters: TR1s (respira-
tion gating), TE ¼ 5 ms(T1-weighted)/16 ms(Phase), FA
¼ 90(T1-weighted)/50(Phase), number of slices ¼ 20
with 0.2-mm gap to avoid cross excitation between sli-
ces. The image resolution in the different regions was
66*66*400 mm3 (Cortex /hippocampus), 58*58*400 mm3
(OB) with a total acquisition time of 8 min (Cortex/hip-
pocampus, OB).
Frequency Shift Maps
To establish the magnetic susceptibility of Mn2þ in the
phantom, frequency shift maps were acquired using a
multi-gradient echo sequence. Fifteen gradient echo
images (4.5 to 60.5 ms) were obtained with the following
parameters: TR ¼ 900 ms, FA ¼ 40, FOV ¼ 30*30 mm2,
resolution ¼ 234*234*800 mm3.
Data Processing
T1 maps were calculated pixel by pixed using a Nelder-
Mead fitting algorithm (25). Due to the coil setup (sur-
face coil) a three-parameter fit (T1, M0 and flip angle a)
was done to take into account the transmit field inhomo-
geneity. Steady state signal was considered in the algo-
rithm to remove any bias from possible magnetization
not fully recovered at the end of the TR. Frequency
maps were established from a linear fit to the phase
change over the 15 echoes. Phase images were
unwrapped (26) and the background field contributions
originating from imperfect shimming, air tissue interfa-
ces were filtered using the SHARP algorithm (17). This
methodology does not remove entirely phase variations
related to the transmitting and receiving B1 field which
can be removed by applying a high pass filter with a
wide Gaussian width.
Phantom Data
Regions of interest (ROIs) were placed within each
MnCl2 tube. The relaxation rate R1 and frequency val-
ues were measured from the respective T1 and fre-
quency maps for each ROI . The different values were
then plotted as a function of [Mn2þ] and a linear regres-
sion was performed to find the longitudinal relaxivity,
r1, of Mn
2þ
R1ð½Mn2þÞ ¼ R1ð0Þ þ r1  ½Mn2þ: [1]
For the frequency map, the outside compartment
([Mn2þ]¼0) was used as a reference. A frequency shift
per millimolar, dfpmM, was calculated
Df ð½Mn2þÞ ¼ dfpmM  ½Mn2þ: [2]
Subsequently, the magnetic susceptibility per millimolar
was calculated using the following expression dfpmM ¼
1/3*gB0xpmM (27), where g is the gyromagnetic con-
stant ratio, which represents the relationship between
the frequency shift difference and the susceptibility dif-
ference for an infinite cylinder aligned along the main
magnetic field.
In Vivo Data
The changes in T1 due to Mn
2þ as a function of the dif-
ferent doses were calculated by selecting ROIs in the cor-
tex, hippocampus, corpus callosum (within the same
slice) and in different fields of the OB (Fig. 4). Although
manganese can be transported by means of the axons
(28), its enrichment in white matter is limited as it
mainly accumulates in synaptic regions of gray matter
(29). To measure the contrast enhancement throughout
the Mn2þ doses, the CNR was calculated as the signal
difference between the tissue of interest and a region
devoid of Mn2þ enhancement (WM) divided by the
standard deviation of the noise (s). The T1-weighted con-
trast of the cortex and dentate gyrus of the hippocampus
were established in respect to the corpus callosum
whereas the contrast of the OB was established by sub-
tracting the signal from the anterior commissure, intra-
bulbar part (aci) (Fig. 4).
Likewise, phase enrichment (DfGM-WM) and phase CNR
were established considering ROI’s in the same slice and
the latter was calculated using the following equation:
CNRphase ¼ Signalav :2p:TE:jfGM -fWM j=s: [3]
With Signalav =(SignalGM þ SignalWM)/2, TE the echo
time used, fGM and fWM the frequency shift of gray matter
and white matter, respectively, and s the standard devia-
tion of the background noise measured outside the brain
within artifact free regions (11).
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RESULTS
Relaxivity r1 and dfpmM of Mn
2þ at 14.1T
To determine the relaxivity parameters of Mn2þ at 14.1T,
the relaxation rates, R1, and frequency shifts, Df, were
measured using a phantom containing seven cylindrical
tubes with Mn2þ concentrations ranging from 0 to 200 mM,
(Fig. 1). Both quantities showed the expected linear rela-
tionship with Mn2þ concentration (R2 > 0.98). The meas-
ured longitudinal relaxivity, r1, was established at 5.5 6
0.1 s1.mM1 (Fig. 1a). The frequency shift as a function
of Mn2þ dfpmM was measured at 251 6 12 Hz.mM
1 (Fig.
1b) resulting in a susceptibility of Mn2þ of 1.25 6 0.06
ppm.mM1.The apparent transverse relaxivity r2* was also
established at 234 6 8 s1.mM1 (data not shown).
Induced Phase and T1 Changes 24h Post Systemic Mn
2þ
Administration
T1-weighted imaging
To qualitatively determine the effect of systemic Mn2þ
administration on T1 contrast, T1-weighted images of the
olfactory bulb, cortex, and hippocampus acquired before
and 24h after a 125 mg/kg systemic Mn2þ administration
were compared (Fig. 2).
Before Mn2þ administration, tissue structures in the OB,
cortex, and hippocampus regions were poorly discernible
despite the high in-plane resolution of 58mm (Fig. 2).
Twenty-four hours after Mn2þ systemic administration,
an overall increase in SNR was observed in all regions (OB:
þ31%; cortex þ38%; hippocampus: þ66%) followed by a
significant increase in tissue contrast in manganese-
enhanced structures. In the OB, several anatomic features
were enhanced andwell depicted such as the external plexi-
form (EPL), internal plexiform (IPL), the mitral cell layer
(ML), granular cell layer (GrL), and olfactory nerve layer
(ONL. Subregional anatomic structures of the hippocampus
were also well visualized with clear depiction of CA1, CA2,
CA3, DG of the hippocampus (black arrows Fig. 2).
Phase imaging
To qualitatively determine the effect of Mn2þ on phase
contrast, phase images acquired before and 24h after a
125 mg/kg Mn2þ administration, in the same slices/
regions of interest as the T1-weighted images, were com-
pared (Fig. 3).
Before Mn2þ administration, the high contrast to noise
ratio (CNR) given by the phase image already enabled to
depict several structures of the olfactory bulb such as the
external plexiform (EPL) and internal plexiform (IPL),
granular cell layer (GrL), and olfactory nerve layer (ONL)
(Fig. 3). Twenty-four hours following Mn2þ administra-
tion, Mn2þ accumulation resulted in an increase of CNR
in all structures rich or with active voltage gated calcium
channels, further enhancing the cytoarchitectural fea-
tures (black arrows Fig. 3) which were already depicted
beforehand with a clear emphasis of the mitral cell layer
(ML) and the glomerular layer (GL).
Likewise, in the cortex-hippocampus region and before
Mn2þ administration, phase imaging yielded substantial
anatomical contrast allowing the identification of hippo-
campus structures, gray matter cortical layer (Fig. 3) and
white matter structures such as the corpus callosum, the
internal capsule, and the fornix (as expected from previ-
ous studies). A phase shift and CNR increase mainly in
the dentate gyrus, CA of the hippocampus and cortical
layer (black arrows Fig. 3) was likewise observed twenty
four hours following Mn2þ administration further
enhancing the cytoarchitectural features which were
already depicted beforehand.
Dose Dependence of T1 and Phase Contrast following
Mn2þ Systemic Administration
To define the effect of the dose of Mn2þ administration
on both T1 and phase images, the Mn
2þ dose was varied
from 0, 25, 75, and 125 mg/kg. Figure 4 shows the corre-
sponding T1 map, phase and T1-weighted images
acquired in the cortex-hippocampus and olfactory bulb
regions with Mn2þ doses ranging from 0 to 125 mg/kg.
At the lowest dose for both phase and T1-weighted
images, enhancement of the CA1, CA2, CA3, and DG of the
hippocampus (Fig. 4a) and external, internal plexiform,
mitral cell, olfactory nerve, and granular cell layers (Fig. 4b)
were already visible. In comparison to the cortex-
hippocampus region, the contrast enhancement in the olfac-
tory bulb was more pronounced for both imaging methods.
FIG. 1. In vitro relaxivity measurements of Mn2þ at 14.1T. a: Longi-
tudinal relaxation rate R1. b: Frequency shift plotted as function of
[Mn2þ]. Error bars represent standard deviations over the regions
of interest. Dashed line represents the linear regression fit to the
data points.
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Such enhancement progressed with the increasing
doses of Mn2þ, offering a better delineation of the
cytoarchitectural features cited above in both imaging
methods. These observations were supported by the
observed T1 decrease in the corresponding T1 maps.
Quantification of the R1 increase is shown in Figure 5a
as the evolution of the relaxation rate DR1 in regions of
Mn2þ enhancement and in white matter as a function of
the Mn2þ dose. (Preinfused R1: Cortex: 0.42s1 6 0.01;
Dentate Gyrus: 0.46s1 6 0.01; Olfactory Bulb: 0.46s1 6
0.03; Corpus callosum: 0.51s1 6 0.02). DR1 was calcu-
lated for a specific ROI as the difference in relaxation
rate between a given Mn2þ dose and preinfusion control.
From 0 mg/kg to 125 mg/kg, DR1s in all regions
increased, with the dentate gyrus showing a greatest
increase indicating a higher Mn2þ uptake followed by
the olfactory bulb and cortex. DR1 of the corpus callosum
showed minimal increase throughout the Mn2þ doses
(þ0.02s1 6 0.03 from 0 to 125 mg/kg).
Figure 5b shows the evolution of the frequency shift
difference Df as a function of Mn2þ dose measured in the
same ROIs as in Figure 5a. Df was calculated in the same
manner as DR1. However, as the frequency is not abso-
lute (due to background field removal), Df was
FIG. 2. Axial T1-weighted images
of the Olfactory Bulb, Cortex
and Hippocampus before and
24h post MnCl2 i.v. systemic
administration (dose of 125 mg/
kg). Pronounced signal and con-
trast enhancement of the brain
cytoarchitecture with clear
depiction of the CA1, CA3, DG
of the hippocampus and olfac-
tory bulb layers (black arrows).
EPL: external plexiform; IPL:
internal plexiform; ML: mitral cell
layer; ONL: olfactory bulb nerve
layer; GrL: granular cell layer;
DG: dentate gyrus.
FIG. 3. Axial gradient echo phases images of the olfactory bulb, cortex and hippocampus before and 24h post MnCl2 i.v. systemic
administration (dose of 125 mg/kg). Pre Mn2þ phase images with in plane resolution of 58 mm/OB and 66 mm/Cortex-hippocampus
region acquired in 8 min show good CNR between GM and WM structures enabling to already depict several tissue structures only
seen in T1-weighted images following Mn
2þ systemic administration. Twenty-four hours post Mn2þ infusion, Mn2þ accumulation in
regions rich or with active calcium channels resulted in a positive phase shift from the induced magnetic susceptibility and an increase
in phase CNR. EPL: external plexiform; IPL: internal plexiform; ML: mitral cell layer; ONL: olfactory bulb nerve layer; GrL: granular cell
layer; DG: dentate gyrus; F: fornix; MT: mammillothalamic tract.
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established by subtracting respectively the frequency
value of the white matter in both Mn2þ and preinfusion
control data (corpus callosum for the cortex and dentate
gyrus; anterior commissure intrabulbar part for the olfac-
tory bulb—yellow regions in Figs. 3 and 4). Again, a
monotonic increase of the frequency difference as a func-
tion of Mn2þ uptake is observed. The smallest increase
of Df was again observed in the cortex. However, in
opposition to DR1, the olfactory bulb showed the greatest
Df increase.
T1-Weighted and Phase CNR Comparison
To compare the sensitivity of phase imaging and T1-
weighted images at 14.1T, the dose dependence of the
CNR was compared for both imaging methods and in the
same regions of interest as described in the “Data Proc-
essing” paragraph. CNR for both imaging methods was
established by subtracting the signal of neighboring
white matter for each region and for each given Mn2þ
dose. Figure 6 and Table 1 show that with increasing
FIG. 4. Dose dependence of MEMRI contrast in cortex-hippocampus region (a) and OB (b) observed in corresponding T1 map,
T1-weighted and phase images taken from the same animal. From the lowest dose of 25 mg/kg, brain cytoarchitecture is enhanced in
both T1-weighted and phase images with improved CNR and SNR which increased with respect to Mn
2þ dose offering clear delineation
of several subregional structures in the hippocampus and olfactory bulb. Signal intensity of T1-weighted images has been normalized by
the standard deviation of the background noise calculated from an artifact free region. Regions of interest drawn for quantification anal-
ysis are shown in the 125 mg/kg images for (a) and (b). [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Mn2þ dose, both phase and T1-weighted CNR increased
progressively in all regions of interest. Globally, phase
contrast outperformed our T1-weighted imaging protocol
showing always greater contrast. Also the CNR increase
was greater in 7 of the 9 regions studied for the phase
contrast when compared with the T1-weighted contrast.
In terms of relative increase of the CNR (relative to the
initial contrast, see values inside the brackets on Table
1) between the control region and the regions with active
Mn2þ uptake, T1-weighted images showed superior frac-
tional CNR increase in 6 of the 9 regions studied.
DISCUSSION
The study reports for the first time the longitudinal
relaxivity parameters (r1) and the magnetic susceptibility
xpmM of Mn
2þ at 14.1T. Magnetic susceptibility values
demonstrate that Mn2þ enhancement could be explored
in phase imaging (Fig. 1). The relaxivity of Mn2þ estab-
lished from the measurements of R1 to varying Mn
2þ
concentrations was in good agreement with r1 reported
at 1.5T (29) and at 11.7T (30).
These in vitro observations were confirmed in vivo
with enhancement of regions rich in voltage gated cal-
cium channels in both phase and T1-weighted images
24h following Mn2þ administration (as seen Figs. 3 and
2, respectively). The results from the T1-weighted images
are consistent with previous MEMRI studies (6,7,10).
Mn2þ enhancement was manifested in T1-weighted imag-
ing by a signal increase due to the reduction in T1. In
phase imaging, Mn2þ uptake not only resulted in
increased frequency shift differences (penultimate term
of Eq. [3]) but also in increased SNR due to the reduction
in T1 (first term of Eq. [3]). Mn
2þ uptake also introduces
a signal attenuation due to T2* decay which could ham-
per, at high magnetic field, the assessment of MEMRI
contrast by phase imaging for high Mn2þ concentrations
and long echo times. However, for the typically Mn2þ
concentrations found in vivo, it should be noted that
this is not a concern as the phase CNR continues to
increase (see Appendix 1). The gain in phase contrast
associated with T1 reduction and increased frequency
shift make phase imaging, and potentially susceptibility
mapping, a promising tool in the field of MEMRI.
FIG. 5. DR1 (a) and Df (b) evolution, function of manganese dose
across different brain regions. For a specific region of interest
(ROI), DR1 and Df were established as follows: DR1(Mn
2þ
dose) ¼
R1(Mn
2þ
dose)- R1(0) with R1(0), preinfusion control R1 value for cor-
responding brain region. Likewise, Df(Mn2þdose) ¼ (f(Mn2þdose)-
fWM(Mn
2þ
dose))- (f(0)- fWM(0)). Df in the dentate gyrus and cortex
was measured by subtracting the WM frequency of the corpus
callosum in both Mn2þ and preinfusion control data. Df of the
olfactory bulb was measured by subtracting the WM frequency of
the anterior commissure, intrabulbar part. From 0 mg/kg to 125
mg/kg, the dentate gyrus showed the highest increase indicating
a higher Mn2þ uptake followed by the olfactory bulb and cortex.
Likewise, a monotonic increase of the frequency difference as a
function of Mn2þ uptake was observed in all regions. The smallest
increase of Df was again observed in the cortex. However, in
opposition to DR1, the olfactory bulb showed the highest Df
increase. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
FIG. 6. Plots of the contrast to noise ratio of T1-weighted (a) and
phase imaging (b) as a function of the manganese dose for differ-
ent brain regions (cortex, dentate gyrus, and olfactory bulb). At
control level and for all regions, phase CNR was significantly
higher than T1-weighted CNR. From 0 to 125 mg/kg, both phase
and T1-weighted CNR increased progressively in all regions of
interest. The cortex exhibited the slowest CNR increase in both
imaging methods while the dentate gyrus and olfactory bulb
showed the highest. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
1252 Maddage et al.
Before Mn2þ infusion, phase imaging, thanks to its
high CNR between and within gray and white matter,
allowed the depiction of structures which are only dis-
cernible after Mn2þ infusion in T1-weighted imaging (see
Figs. 2 and 3). Furthermore, other tissue structures such
as white matter fiber tracts (fornix and mamillothalamic
tract) not detectable on T1-weighted images both before
and after Mn2þ enhancement were clearly discernible in
phase images. Overall, by further increasing phase CNR
which was, before Mn2þ infusion, higher than in the T1-
weighted imaging, Mn2þ infusion enabled to further
explore the brain structure and give additional informa-
tion in comparison to the used T1-weighted imaging pro-
tocol. As such, Mn2þ can be considered as a MR phase
contrast agent used to enhance neuro-architectonic
contrast.
Twenty-four hours following Mn2þ administration, vei-
nous structures were more pronounced, indicating an
increase of susceptibility present in the veins that could
be either due to an increase in the deoxyhemoglobin or
manganese concentration. Independently of the origin of
such vessel susceptibility changes, it has been shown
that point-like susceptibility inclusions inside the vascu-
lature contribute only to a very small extent to the phase
contrast between gray and white matter (13,31). Its con-
tribution can be ruled out making the observed increase
of contrast in tissue to be associated to the Mn2þ uptake
in those regions.
The sensitivity of phase-based Mn2þ enhancement at
14.1T was also studied at different Mn2þ doses and com-
pared with T1-weighted imaging in different brain ROIs.
Qualitatively in Figures 3 and 4, contrast in regions rich
or with active voltage gated calcium channels such as
the dentate gyrus, cortex, and olfactory bulb continued
to increase with the increasing Mn2þ doses for both
imaging methods offering a better delineation of the
cytoarchitectural features. Quantification of R1 changes
from the T1 maps, in the selected brain regions cited
above, indicated a heterogeneous R1 increase/Mn
2þ
uptake throughout the Mn2þ doses with the cortex exhib-
iting the smallest increase and the olfactory bulb and
dentate gyrus the strongest increase (Fig. 5a and Table
1). These results are in agreement with a previous study
made by Lee et al (9). The very low, but constant, R1
increase observed in the corpus callosum (þ0.02s1 6
0.03 from 0 to 125 mg/kg) is a confirmation of the very
weak presence of voltage gated calcium channels in
white matter (32). Mn2þ distribution by means of the cer-
ebrospinal fluid and paravascular spaces following sys-
temic administration are the main pathways of Mn2þ
enhancement in the rat brain (9). Nonspecific diffusion
of Mn2þ ions might have an influence on the minimal R1
increase seen in the corpus throughout the Mn2þ doses.
Alternatively, it could also be a consequence of the rela-
tively low resolution of the T1 maps and the point
spread function due to the EPI readout, making the
increase in R1 observed in the WM simply a partial vol-
ume effect. Nevertheless, the corpus callosum R1
increase was very weak (when compared with the
remaining regions) and could be considered non signifi-
cant for the CNR study. From 0 to 125 mg/kg, both Df
and DR1 increased monotonically in all regions despite
correlation between DR1 and Df being different in the
selected brain regions (8.8 in cortex, 5.4 in the DG and
13.1 in the OB). Nonetheless, the increase in contrast
observed in the DR1 and Df (see Fig. 5), when taking into
account the phantom study results (Fig. 1), suggest Mn2þ
enrichments are of the same order of magnitude, further
supporting a close association between R1, frequency
shift increase and Mn2þ uptake. For the maximum Mn2þ
dosage (125 mg/Kg), assuming relaxivity values hold in
vivo, the following enrichments can be calculated:
21 mM in the Cortex, 63 mM in the DG, and 37 mM in
the OB.
The evaluation of the CNR increase following Mn2þ
administration indicated that, overall, from 0 to 125 mg/
kg, Mn2þ enhancement was more pronounced in phase
imaging than in T1-weighted imaging protocol used
although its fractional increase was greater for the latter
(see Table 1). This observation is highly dependent on
the sequence and parameters used to obtain the T1-
weighted images. In this study, a gradient echo with a
fixed TR of 1 second was applied to avoid respiration
induced artifacts, under such constraints the optimal flip
angle to obtain T1 contrast is 90. Had our setup
allowed for a three-dimensional acquisition, a TR as
short as 10 ms could have been used together with an
excitation of 11 which would have increased our con-
trast per unit of time to the DR1 by 10%. Other studies
in literature have used spin echo sequences (9,10) or
inversion recovery sequences (4). The use of a gradient
echo with a short echo time was preferred to a spin echo
sequence due to the B1 inhomogeneity associated with
the use of a surface coil. The signal from a spin echo
sequence has a sin3(90*B1) dependence on B1 (33), sig-
nificantly limiting the range over which acceptable SNR
Table 1
Mn2þ Dose Dependence T1-Weighted and Phase CNR Values in Different Brain Regions in Respect to Neighboring White Matter Regions
a
Mn2þ
dose
(mg/kg)
Cortex Dentate gyrus Olfactory bulb
T1W CNR Phase CNR T1W CNR Phase CNR T1W CNR Phase CNR
0 8.3 6 1.4 22.8 6 5.0 2.0 6 1.0 14.3 6 2.9 3.2 6 1.2 29.3 6 6.3
25 8.5 6 1.9 (2.4%) 22.9 6 2.7 (0.4%) 2.4 6 1.0 (20.0%) 14.5 6 1.6 (1.4%) 4.0 6 0.6 (25.0%) 35.5 6 4.1 (21.2%)
75 8.8 6 1.8 (6.0%) 29.9 6 1.8 (31.1%) 4.1 6 1.0 (105.0%) 27.2 6 7.1 (90.2%) 4.9 6 0.3 (53.0%) 48.1 6 3.1 (64.2%)
125 10.1 6 1.7 (21.7%) 39.4 6 0.8 (72.8%) 7.6 6 1.8 (280.0%) 41.2 6 4.8 (188.1%) 9.2 6 1.3 (187.5%) 62.7 6 2.6 (114%)
aIn between brackets, the percentage increase of contrast in respect to the contrast observed in absence of Mn2þ administration is
shown.
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and T1-weighting would be achieved on our setup and
which can only be overcome by the usage of adiabatic
refocusing pulses (34). A gradient echo sequence intro-
duces a Mn2þ related signal attenuation due to T2*
decay. The reduction in contrast due to the use of a gra-
dient echo sequence (given an apparent transverse relax-
ivity of Mn2þ) is bound to be smaller than 50% for the
largest Mn2þ dose, not enough to justify the 4–7 times
reduction in T1-weighted contrast in respect to phase
found in Table 1. Although it has been demonstrated
inversion recovery-based sequences (such as the
MPRAGE) offer superior T1-contrast with reduced sensi-
tivity to B1 homogeneity thanks to the use of adiabatic
inversion pulses and efficient low flip angle excitations
for the readout, analytical analysis of the contrast effi-
ciency (35) of the spoiled gradient echo used in this
study versus an MPRAGE sequence with the same echo
time, constraint of 128 phase encoding steps per excita-
tion (TR ¼ 2–4 s, flip angle ¼ 8 TI ¼ 1.5 s) showed that
the MPRAGE would not necessarily provide an
improved T1-weighted contrast in comparison to our pro-
tocol when considering the typical relaxation parameters
measured in the dentate gyrus (R1 of 0.46 s
1 and a DR1
of 0.35s1 following Mn2þ systemic administration at
maximum dose of 125 mg/kg). It is important to point
out that, as the magnetic susceptibility induced fre-
quency shift is linearly dependent to the static magnetic
field, at lower magnetic fields (such as the typically
available for animal scanning 4.7–7T), the CNR of the
phase contrast will be lower and it remains to be deter-
mined at which field strength an optimized T1-weighted
imaging protocol is likely to outperform phase imaging.
One of the pitfalls of in vivo phase imaging is its sensi-
tivity to physiology and respiration induced artifacts due
to the long echo time used. In our study, such artifacts
were minimized by using respiration triggering. Another
important limitation of phase imaging is the difficulty of
obtaining reliable values in regions close to air/tissues
interfaces such as the olfactory bulb. Despite the care
taken when performing background filtering, the phase
image in the olfactory bulb is pronouncedly affected by
phase variations arising from air/tissue interfaces making
structures situated at the extremities (such as the olfactory
glomeruli, the glomerular layer) difficult to discern.
Phase-based MEMRI can, potentially, offer a higher
resolution and contrast than that obtainable with T1-
weighted imaging and be equally quantitative. To make
phase-based Mn2þ quantification, it would be important
to perform a quantitative susceptibility mapping (36,37).
The lack of this step on our analysis is likely to explain
the difference in ordering observed between the fre-
quency shift enhancement in the olfactory bulb, hippo-
campus, and in R1 maps. The measured frequency shift
reflects not only the local increase of the Mn2þ uptake,
but also its geometrical shape in respect to the static
magnetic field. To be able to compute susceptibility
maps, it would be beneficial to obtain a closer to iso-
tropic resolution and bigger coverage than what was
achievable with a surface coil. Two of the main difficul-
ties when evaluating susceptibility maps is the fact that
the forward model (role of macromolecular contribution
(15), anisotropic susceptibility (38), and microstructure
(14)) is not fully understood and that the susceptibility
values should be always seen as relative measure. In the
case of studying Mn2þ uptake, Mn2þ can be considered
as simple isotropic susceptibility contrast agent while
any other bias of the QSM method will be the same prior
and post to Mn2þ infusion. Also, from the results
observed in this study using R1 mapping (see Fig. 5a),
white matter structures would form an ideal reference
throughout the enrichment. Such an approach would
offer fully quantitative Mn2þ uptake maps.
CONCLUSIONS
We conclude from the present study that MEMRI can be
assessed by phase imaging at high magnetic field.
Although Mn2þ had a stronger effect on T1-weighted
imaging, phase imaging demonstrated to have superior
CNR following Mn2þ systemic administration. Future
work will be directed toward exploring high resolution
and high contrast manganese enhanced phase images to
obtain quantitative manganese uptake information by
using quantitative susceptibility mapping.
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APPENDIX 1
For a given echo time and as [Mn2þ] increases, the
increased magnetic susceptibility induces an increase in
phase but also a reduction in gradient echo (GRE) signal
intensity due to T2* attenuation. As phase CNR is corre-
lated to both magnitude SNR and phase difference for a
given echo time, MEMRI assessment by phase imaging at
ultra-high field could be hampered by high [Mn2þ] if the
reduction in T2* is large, relative to the echo time used.
To address this point, simulations were performed using
a range of Mn2þ concentrations going beyond those
found in the in vivo rodent brain following Mn2þ sys-
temic administration (30). The GRE signal was simulated
using the relaxation parameters experimentally found for
the Dentate Gyrus (R1control, DR1 at maximum dose of
125 mg/kg) and Mn2þ relaxivities (reported in Section
Relaxivity r1 and dfpmM of Mn
21 at 14.1T). The GRE mag-
nitude CNR was defined as the signal difference prior
and post Mn2þ infusion (125 mg/kg). Phase CNR was
defined similarly and as described in Eq. [3].
Figure A1 (a, b) shows the expected magnitude CNR for
a 90 degree and Ernst angle setting respectively. As
expected, in both cases the maximum GRE CNR is at
TE ¼ 0. However, due to the T2* decay, a very fast CNR
decrease is observed for the Ernst angle setting resulting
in a decrease of magnitude signal as the echo time
increases for high Mn2þ concentration. However, this
decrease in signal intensity does not suggest a reduction
of the phase CNR as it can be observed in Figure A1c.
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Nevertheless it suggests that the optimum echo time
should be reduced for higher Mn2þ concentrations (as
shown by the black line). The optimum echo time
decreases from 16 ms to 8 ms (at [Mn2þ] ¼ 0.3 mM) due
to the T2* decay. The plot in Figure A1d shows that, if
the optimum echo at pre-Mn2þ infusion is indeed kept
constant, the phase CNR starts to saturate at high con-
centrations of Mn2þ (as shown by the dark gray line)
although the frequency difference would continue to
increase linearly.
Consequently, the use of a shorter echo time for post
Mn2þ enrichment would have been preferable as it can
be observed at TE ¼ 8 ms where the phase CNR evolu-
tion is close to optimum (light gray line). However,
when taking into account the range of Mn2þ concentra-
tion obtained in the study (0 to 0.064 mM), at TE ¼ 16
ms no saturation effect is observed as the phase CNR
increased linearly with the increased tissue [Mn2þ].
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